A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose ...

Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Pemafibrate was ...

Charcot foot is a disease that causes weakness of the bones and joints. It commonly affects the middle of the foot, the hindfoot joint, and the ankle and forefoot joints. Charcot foot, also known as ...

A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors have a slightly lower risk of developing ...

For adults with type 2 diabetes mellitus (T2DM), new users of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) hav ...